Long acting GLP-1 receptor agonist (injectable)
Semaglutide 2.4 mg subcutaneous once weekly
SEMA_SC_2p4MG_QW
Related
- All doses pooled: Semaglutide injection
- Semaglutide 1.0 mg subcutaneous once weekly
- Semaglutide maximum tolerated dose injection once weekly
- Semaglutide 0.5 mg subcutaneous once weekly
- Semaglutide 0.5 mg injection
- Semaglutide flexible dose injection once weekly
- Semaglutide 0.4 mg injection once daily
- Semaglutide 0.1 mg injection once daily
- Semaglutide 0.2 mg injection once daily
- Semaglutide 0.25 mg injection
- Semaglutide 2.0 mg subcutaneous once weekly
- Semaglutide 1.5 mg injection once weekly
- Semaglutide 8 mg injection once weekly
- Semaglutide 16 mg injection once weekly
- Semaglutide 0.1072 mg injection
- Semaglutide 1.7 mg injection once weekly
- Semaglutide flexible dose injection once weekly
- Semaglutide 0.05 mg injection once daily
- Semaglutide 0.3 mg injection once daily
- Semaglutide flexible dose injection once weekly
- Semaglutide 2.4 mg injection
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.98 (0.11 to 7.43) | 0.34 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.42 (0.59 to 3.58) | 0.49 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.98 (0.25 to 3.71) | 0.49 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD -2.38 (-14.32 to 9.61) | 0.54 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.58 (0.38 to 0.86) | 0.75 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.31 (0.65 to 2.66) | 0.57 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 2.19 (0.86 to 5.92) | 0.46 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 2.05 (0.27 to 17.41) | 0.28 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 40 to 104 (target week 68) | Placebo | MD -6.27 (-8.59 to -4.23) | 0.77 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -6.94 (-18.90 to 5.51) | 0.67 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 40 to 104 (target week 68) | Placebo | MD -1.09 (-12.81 to 10.28) | 0.54 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -14.17 (-20.83 to -5.40) | 0.51 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -12.10 (-13.88 to -10.75) | 0.82 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -12.09 (-14.49 to -9.28) | 0.71 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -12.61 (-16.72 to -7.57) | 1.00 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -8.68 (-14.57 to -2.79) | 0.56 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 8.15 (2.84 to 19.02) | 0.63 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 19.68 (10.75 to 29.70) | 0.59 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 9.31 (2.11 to 31.30) | 0.99 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 104 to 182 (target week 104) | Placebo | OR 6.13 (1.80 to 16.00) | 0.99 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 16.62 (11.07 to 26.51) | 0.76 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 15.76 (3.51 to 37.51) | 0.79 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 104 to 182 (target week 104) | Placebo | OR 9.87 (2.66 to 29.12) | 0.85 |
| Overweight or obesity without diabetes (adults) | Weight loss of 15 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 13.02 (8.93 to 20.10) | 0.73 |
| Overweight or obesity without diabetes (adults) | Weight loss of 15 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 18.71 (5.83 to 42.46) | 0.87 |
| Overweight or obesity without diabetes (adults) | Weight loss of 20 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 16.71 (10.02 to 29.74) | 0.81 |
| Overweight or obesity without diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 2.19 (-5.09 to 9.80) | 0.67 |
| Overweight or obesity without diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 0.73 (-0.64 to 2.07) | 0.38 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.21 (0.85 to 1.70) | 0.48 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 2.01 (1.15 to 3.41) | 0.49 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.58 (3.03 to 4.31) | 0.50 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 4.35 (3.34 to 5.85) | 0.50 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.09 (1.69 to 2.63) | 0.46 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.84 (2.16 to 3.91) | 0.35 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 5.56 (2.31 to 15.14) | 0.26 |
| Overweight or obesity without diabetes (adults) | Gallbladder and biliary disease | longest follow-up | Placebo | HR 2.38 (1.09 to 5.43) | 0.35 |
| Weight maintenance after a GLP-1 receptor agonist containing run in | Nausea | longest follow-up | Placebo | HR 0.65 (0.01 to 51.04) | 0.68 |
| Weight maintenance after a GLP-1 receptor agonist containing run in | Vomiting | longest follow-up | Placebo | HR 1.58 (0.09 to 17.06) | 0.49 |
| Weight maintenance after a GLP-1 receptor agonist containing run in | Diarrhea | longest follow-up | Placebo | HR 14.37 (0.95 to 327) | 0.03 |
| Weight maintenance after a GLP-1 receptor agonist containing run in | Constipation | longest follow-up | Placebo | HR 2.50 (0.11 to 33.07) | 0.41 |
| Children and adolescents with obesity | BMI standard deviation score change | weeks 40 to 104 (target week 68) | Placebo | MD -0.96 (-1.27 to -0.53) | 0.99 |
| Children and adolescents with obesity | Serious adverse events | longest follow-up | Placebo | HR 1.31 (0.33 to 5.40) | 0.41 |
| Children and adolescents with obesity | Nausea | longest follow-up | Placebo | HR 2.71 (0.77 to 8.79) | 0.44 |
| Children and adolescents with obesity | Vomiting | longest follow-up | Placebo | HR 3.82 (0.97 to 13.87) | 0.58 |
| Children and adolescents with obesity | Diarrhea | longest follow-up | Placebo | HR 1.15 (0.37 to 3.80) | 0.62 |
| Children and adolescents with obesity | Constipation | longest follow-up | Placebo | HR 3.31 (0.48 to 33.74) | 0.29 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Serious adverse events | longest follow-up | Placebo | HR 1.53 (0.31 to 10.18) | 0.39 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Discontinuation due to adverse events | longest follow-up | Placebo | HR 4.97 (0.38 to 128) | 0.23 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Nausea | longest follow-up | Placebo | HR 3.15 (0.89 to 12.87) | 0.47 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Vomiting | longest follow-up | Placebo | HR 10.37 (1.03 to 248) | 0.28 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Diarrhea | longest follow-up | Placebo | HR 2.37 (0.49 to 14.13) | 0.35 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Constipation | longest follow-up | Placebo | HR 0.78 (0.12 to 5.87) | 0.79 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 3.41 (0.23 to 94.54) | 0.38 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Resolution of steatohepatitis without worsening of fibrosis | weeks 48 to 104 (target week 72) | Placebo | OR 1.90 (0.41 to 9.36) | 0.42 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Fibrosis improvement without worsening of steatohepatitis | weeks 48 to 104 (target week 72) | Placebo | OR 0.31 (0.06 to 1.71) | 0.08 |
Trials
- S0034372025 · 180 randomized · 24 weeks
- BARI-STEPBARI-STEP:A Double-blinded, Randomised, Placebo-controlled Trial of Semaglutide 2.4 mg in Patients With Poor Weight-loss Following Bariatric Surgery.2022 · 70 randomized · 68 weeks
- NCT05616013A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Intravenous Bimagrumab, Alone or in Addition to Open Label Subcutaneous Semaglutide, to Investigate the Efficacy and Safety in Overweight or Obese Men and Women2022 · 507 randomized · 48 weeks
- STABLE Wt LossShort- and Long-term Effects of Once Weekly Semaglutide 2.4 mg on Appetite, Eating Behavior, and Psychosocial Status2022 · 120 randomized · 60 weeks
- STEP 10Efficacy and Safety of Subcutaneous Semaglutide 2.4 mg Once-weekly in Subjects With Obesity and Prediabetes2021 · 207 randomized · 52 weeks
- STEP HFpEF DMEffect of Semaglutide 2.4 mg Once-weekly on Function and Symptoms in Subjects With Obesity-related Heart Failure With Preserved Ejection Fraction, and Type 2 Diabetes2021 · 616 randomized · 52 weeks
- STEP7Effect and Safety of Semaglutide 2.4 mg Once-weekly on Weight Management in Subjects With Overweight or Obesity.2020 · 375 randomized · 44 weeks
- NCT03842202Effect of Semaglutide 2.4 mg Once-weekly on Gastric Emptying in Subjects With Obesity2019 · 72 randomized · 20 weeks
- STEP 8Effect and Safety of Subcutaneous Semaglutide 2.4 mg Once Weekly Compared to Liraglutide 3.0 mg Once Daily on Weight Management in Subjects With Overweight or Obesity2019 · 338 randomized · 68 weeks
- NCT03987451Investigation of Efficacy and Safety of Semaglutide s.c. Once-weekly Versus Placebo in Subjects With Non-alcoholic Steatohepatitis and Compensated Liver Cirrhosis2019 · 71 randomized · 48 weeks
- STEP 6Effect and Safety of Semaglutide Once-weekly in East Asian Subjects With Overweight or Obesity2019 · 401 randomized · 68 weeks
- NCT04102189Effect and Safety of Semaglutide 2.4 mg Once Weekly on Weight Management in Adolescents With Overweight or Obesity2019 · 201 randomized · 68 weeks
- STEP 1Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity2018 · 1,961 randomized · 68 weeks
- STEP 3Effect and Safety of Semaglutide 2.4 mg Once-weekly as Adjunct to Intensive Behavioural Therapy in Subjects With Overweight or Obesity2018 · 611 randomized · 68 weeks
- STEP 5Two-year Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity2018 · 304 randomized · 104 weeks